CMS' final rule includes an NACDS-backed provision to strengthen patient access to care.
Since being hired by the UFC in 2015, Jeff Novitzky has crafted and implemented the strictest drug-testing program in professional sports conducted by the U.S. Anti-Doping Agency.
The Ensuring Patient Access and Effective Drug Enforcement Act of 2016 seeks to increase collaboration between health and enforcement bodies on drug abuse solutions.
A new bill looks to push the FDA into rewriting a guidance on generic drug and biosimilar naming by withholding funding unless it meets Congress’ requests.
DSN examines chain pharmacy, including in-depth coverage of specialty pharmacy, orphan drugs and biosimilars, in this multi-page report.
In 2015, the OGD granted 580 approvals and 146 tentative approvals, including 99 in December alone – the largest number of drug approvals given out in a single month.
Biologic medications — nine of which were among the Food and Drug Administration’s approvals in 2015 — constitute a big portion of the specialty market.
In the last two years, the FDA has broken its record for the approval of orphan drugs to treat diseases that affect 200,000 or fewer people.
It’s no secret that the category of drugs drawing the most attention — and money — in recent years has been specialty pharmacy.
In February, CEO Update named National Association of Chain Drug Stores president and CEO Steve Anderson Trade Association CEO of the Year. DSN looks at some of the more important work accomplished by NACDS under Anderson’s leadership.